TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06075628

Intervention type: OTHER
Intervention: Left Atrial Appendage Occlusion
Description: Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.

Intervention type: OTHER
Intervention: Left Atrial Appendage Occlusion
Description: Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
Study: NCT05425810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apply ENABLE sensing pad
Description: The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
Study: NCT06577103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)
Description: Patients will receive pericapsular nerve group (PENG) block with supra-inguinal fascia iliaca (SIFIC) block.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)
Description: Patients will receive pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block.
Study: NCT05120284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate (DCA)
Description: Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate (DCA)
Description: Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype
Description: Participants will be genotyped to determine GSTZ1 haplotype status.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype
Description: Participants will be genotyped to determine GSTZ1 haplotype status.
Study: NCT04890093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-866
Description: PEN-866 will be given as an IV infusion once every week for the first two consecutive weeks out of every three-week (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-866
Description: PEN-866 will be given as an IV infusion once every week for the first two consecutive weeks out of every three-week (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be given at a dose of 1.5 mg/m2 by IV on days 1 and 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be given at a dose of 1.5 mg/m2 by IV on days 1 and 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide will be given at a dose of 100 mg/m2, orally on days 1-5, of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide will be given at a dose of 100 mg/m2, orally on days 1-5, of each 21-day cycle
Study: NCT06638710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral administration of midazolam or placebo
Description: If the patient is opposed to a treatment (resistance to care ≥3 on the Pittsburgh scale), the nurse administers an oral dose of midazolam or placebo to the patient according to the random allocation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral administration of midazolam or placebo
Description: If the patient is opposed to a treatment (resistance to care ≥3 on the Pittsburgh scale), the nurse administers an oral dose of midazolam or placebo to the patient according to the random allocation.
Study: NCT06173063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobility+ Enteral Feeding System
Description: Enteral feeding using a continuous feeding, self-powered, discreet, silent enteral feeding system.
Study: NCT05425810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insert small pads at pressure tolerant locations
Description: To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
Study: NCT04741984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-201-GBM monocyte vaccine
Description: monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)
Study: NCT05723029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen Technique
Description: A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation
Description: Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
Study: NCT05437718

Intervention type: OTHER
Group type: OTHER
Intervention: Ropivacaine
Description: Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
Study: NCT06515496

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Scale HLV Clinical Formula Hair Vitamins
Description: For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
Study: NCT06566625

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI (CMR) examination
Description: An MRI examination of the heart (CMR) is presently performed as a follow-up examination in patients where an invasive coronary angiography (ICA) shows no obstructive findings. The intervention in this study is characterized by having the CMR performed before, rather than after, the ICA.~In addition, this study will implement some novel CMR sequences which have not been previously tested in this patient cohort:~* CMR Angiography (imaging the coronary arteries using MRI)~* CMR Fingerprinting (sequences which perform T1 and T2 mapping simultaneously)
Study: NCT06656390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK201
Description: Administered intravenously, once every 3 weeks
Study: NCT06649812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo optional tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study: NCT05471973

Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary Team
Description: Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
Study: NCT06649812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06658275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Description: During the first routine checkup, therapists will educate caregivers on how to perform the exercises and activities at home. Caregivers will place the childrens less-affected hands in slings and guide them through exercises designed to engage their weaker, paretic hands. The sling will be fastened around the childrens trunks, with the end securely closed.After the initial session, the intervention will be provided by the caregiver at home, with progress monitored by the therapist through Zoom meetings or WhatsApp video calls. Children will engage in play-based activities as part of the CIMT program to improve upper limb functions.These activities will include painting, pin the tail on the donkey for sensory awareness and proprioception, card games, bubble activities, squeezing sponges, building towers with blocks, playing a curtained box game, using tongs, and picking up coins. Exercises will be gradually progressed from easier to more challenging tasks as the child improves.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Arm Bimanual Intensive Training -HABIT
Description: For the Bimanual Intensive Training group, a strategy similar to HABIT will be used. At the first routine checkup, therapists will educate caregivers on the exercises, which will then be conducted at home. Caregivers will guide children through specially designed bimanual activities without slings, focusing on tasks like reaching, grasping, manipulation, releasing, and bearing weight on the upper limb. Progress will be monitored remotely through Zoom or WhatsApp video calls.Exercises will include catching and throwing a ball to improve reaching, grasp, and release; squeezing a textured ball for sensory awareness and sustained grip; stabilising and reorienting paper while drawing and cutting to enhance forearm supination and wrist extension. Additional tasks like sticker peeling for pincer grip and dough playing for hand manipulation will also be included.Exercises will progress from easy to more difficult as the child improves
Study: NCT05760924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement
Description: The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing
Description: The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing
Description: The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
Study: NCT06607692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib; 177Lu-DOTATATE
Description: 7Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \&gt;= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]). Olaparib will be administered PO, BID, days 2-29, every 8 weeks at a fixed dose of 187.5mg/m2 twice daily (BID).
Study: NCT06277466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs
Description: Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs
Description: The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.
Study: NCT05243810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPC Silver Wound Gel
Description: Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
Study: NCT05037409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859
Description: low dose or high dose intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859
Description: low dose or high dose intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT06111131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enteroscopy
Description: A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enteroscopy
Description: A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.
Study: NCT05471973

Intervention type: OTHER
Group type: OTHER
Intervention: Outreach Visits
Description: An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions

Intervention type: OTHER
Group type: OTHER
Intervention: Multifaceted Intervention
Description: These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement and Feedback
Description: The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
Study: NCT06127420

Intervention type: OTHER
Intervention: coronary physiological indices
Description: Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
Study: NCT05407545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current prosthesis
Description: A unilateral transfemoral amputee will conduct experiments with the current prosthesis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Prosthesis (PowerKnee)
Description: A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
Study: NCT06280859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hoosier Sport
Description: Hoosier Sport is a sport-based youth development intervention. The intervention targets physical activity levels, exercise and nutrition knowledge, and leadership skills. The intervention is delivered in person twice a week (Tue/Thu) during PE class. Each class lasts 45-minutes, and covers sport skills, and then a brief lecture and activity on exercise/nutrition/leadership skills. Additionally, once a week Hoosier Sport is delivered virtually (via Zoom) during home room for 20-minutes. This involves activities to allow the students to be active during the school-day.
Study: NCT06583174

Intervention type: BEHAVIORAL
Intervention: Breastfeeding Attitudes
Description: Relationship between Breastfeeding Attitudes and Nutrition Knowledge Levels
Study: NCT05961956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVDX3
Description: NVDX3 is implanted during a single surgical intervention.
Study: NCT05539950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation
Description: Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.